Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*Jean‐Louis Vincent, Jonathan Janes, David P. Sundin et al.|Critical Care Medicine|2005Cited by 321